
==== Front
Sao Paulo Med J
Sao Paulo Med J
Sao Paulo Med J
São Paulo Medical Journal
1516-3180
1806-9460
Associação Paulista de Medicina - APM

23538600
10.1590/S1516-31802013000100013
Cochrane Highlights
Interventions for primary (intrinsic) tracheomalacia in children
Goyal Vikas
Masters Brent I.
Chang Anne B.
The independent commentary was written by Saramira Cardoso Bohadana

Saramira Cardoso Bohadana. Otorhinolaryngologist and Fellow in Pediatric Laryngology, Voice and Airways. Collaborating Physician in the Department of Otorhinolaryngology, Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo, Brazil.

01 2 2013
2013
131 1 6666
https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons license.
ABSTRACT

BACKGROUND:

Tracheomalacia, a disorder of the large airways where the trachea is deformed or malformed during respiration, is commonly seen in tertiary paediatric practice. It is associated with a wide spectrum of respiratory symptoms from life-threatening recurrent apnoea to common respiratory symptoms such as chronic cough and wheeze. Current practice following diagnosis of tracheomalacia includes medical approaches aimed at reducing associated symptoms of tracheomalacia, ventilation modalities of continuous positive airway pressure (CPAP) and bi-level positive airway pressure (BiPAP), and surgical approaches aimed at improving the calibre of the airway (airway stenting, aortopexy, tracheopexy).

OBJECTIVES:

To evaluate the efficacy of medical and surgical therapies for children with intrinsic (primary) tracheomalacia.

METHODS:

Search: The Cochrane Airways Group searched the Cochrane Central Register of Controlled Trials (CENTRAL), the Cochrane Airways Group’s Specialized Register, Medline and Embase databases. The Cochrane Airways Group performed the latest searches in March 2012.

Selection criteria: All randomized controlled trials (RCTs) of therapies related to symptoms associated with primary or intrinsic tracheomalacia.

Data collection and analysis: Two reviewers extracted data from the included study independently and resolved disagreements by consensus.

MAIN RESULTS:

We included one RCT that compared nebulized recombinant human deoxyribonuclease (rhDNase) with placebo in 40 children with airway malacia and a respiratory tract infection. We assessed it to be a RCT with overall low risk of bias. Data analyzed in this review showed that there was no significant difference between groups for the primary outcome of proportion cough-free at two weeks (odds ratio (OR) 1.38; 95% confidence interval (CI) 0.37 to 5.14). However, the mean change in night time cough diary scores significantly favoured the placebo group (mean difference (MD) 1.00; 95% CI 0.17 to 1.83, P = 0.02). The mean change in daytime cough diary scores from baseline was also better in the placebo group compared to those on nebulized rhDNase, but the difference between groups was not statistically significant (MD 0.70; 95% CI -0.19 to 1.59). Other outcomes (dyspnoea, and difficulty in expectorating sputum scores, and lung function tests at two weeks also favoured placebo over nebulized rhDNase but did not reach levels of significance.

AUTHORS’ CONCLUSIONS:

There is currently an absence of evidence to support any of the therapies currently utilised for management of intrinsic tracheomalacia. It remains inconclusive whether the use of nebulized rhDNase in children with airway malacia and a respiratory tract infection worsens recovery. It is unlikely that any RCT on surgically based management will ever be available for children with severe life-threatening illness associated with tracheomalacia. For those with less severe disease, RCTs on interventions such as antibiotics and chest physiotherapy are clearly needed. Outcomes of these RCTs should include measurements of the trachea and physiological outcomes in addition to clinical outcomes.
==== Body
pmcThis is the abstract of a Cochrane Review published in the Cochrane Database of Systematic Reviews (CDSR) 2012, issue 10, art. No. CD005304. DOI: 10.1002/14651858.CD005304.pub (http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005304.pub3/abstract?systemMessage=Wiley+Online+Library+will+be+disrupted+on+17+December+from+at+23%3A00+GMT+%2818%3A00+EST%29+for+essential+maintenance+for+approximately+one+hour). For full citation and authors details see reference 1.

The full text is freely available, for Latin America and the Caribbean, from: http://cochrane.bvsalud.org/cochrane/main.php?lib=COC&searchExp=Interventions%20and%20for%20and%20primary%20and%20(intrinsic)%20and%20tracheomalacia%20and%20in%20and%20children&lang=pt (this link may be temporary)

COMMENTS: This systematic review evaluated the efficacy of medical and surgical therapies for children with primary intrinsic tracheomalacia.

There is currently a lack of evidence to support any of the clinical or surgical therapies used for management of intrinsic tracheomalacia. For patients with less severe disease who present infection of the lower airways, antibiotics and chest physiotherapy may be effective.

One randomized controlled trial comparing nebulized recombinant human deoxyribonuclease (rhDNase) with placebo showed that this treatment did not produce any significant improvement in symptoms. This review showed that there are no controlled trials presenting evidence regarding clinical therapy for intrinsic tracheomalacia. Each case needs to be assessed individually to determine the kind of treatment (clinical or surgical) that should be applied.
==== Refs
REFERENCE

1 Goyal V Masters IB Chang AB Interventions for primary (intrinsic) tracheomalacia in children Cochrane Database Syst Rev 2012 10 CD005304 CD005304 23076914
